BeOne's Innovative Pipeline Progress Investor R&D Day JUNE 26, 2025 Forward-looking Statements Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, constitute forward looking statements. Examples of such forward-looking statements include statements regarding the projected size of the oncology market and related sectors; BeOne's research, discovery, pre-clinical and early-stage clinica ...

Flash | | Price (07 May 25 16:00) | US$232.25 | | --- | --- | | Target price | US$345.00 | | Expected share price return | 48.5% | | Expected dividend yield | 0.0% | | Expected total return | 48.5% | | Market Cap | US$23,004M | Yigal Nochomovitz, Ph.D.AC +1-212-816-1441 yigal.nochomovitz@citi.com 07 May 2025 22:56:30 ET │ 10 pages BeiGene (ONC.O) Well-Positioned for The Long Game. Brukinsa Surpasses Calquence & Imbruvica in US Qtrly Sales, Reiterate Buy CITI'S TAKE The transformation to a global, Swiss-domi ...

百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新 型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。 最新一期业绩显示，2024年年报，公司实现营业收入272.14亿元，同比56.19%；净利润-4978287000.0 元，同比25.87%，销售毛利率84.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5百济神州-107.93-68.6114.133415.76亿行业平均 57.1245.149.65181.98亿行业中值38.7236.382.8270.20亿1优宁维-1983.75246.701.2225.04亿2万泰生 物-1133.45770.856.71818.91亿3仁度生物-149.58-197.131.6915.40亿4诺思兰德-115.65-104.0514.5347.01亿 6通化东宝-97.77-339.242.23144.93亿7诺诚健华-82.24-82.245.39362.38亿8双鹭药业-68.92-91.411.2167.70 亿9康希诺-62.76-36.502.82 ...

Core Insights - BeiGene, Ltd. reported $1.12 billion in revenue for Q1 2025, marking a 48.6% year-over-year increase and an EPS of $1.22 compared to -$2.41 a year ago [1] - The revenue matched the Zacks Consensus Estimate of $1.12 billion, resulting in a slight surprise of -0.65%, while the EPS exceeded expectations with a surprise of +271.83% [1] Financial Performance - Product revenue totaled $1.11 billion, slightly below the estimated $1.12 billion by analysts [4] - Key product revenues included: - BRUKINSA (Zanubrutinib): $791.66 million vs. $820.07 million estimated - Tislelizumab: $171.16 million vs. $171.33 million estimated - XGEVA: $70.42 million vs. $56.55 million estimated - Other: $17.90 million vs. $14.28 million estimated - POBEVCY: $13.75 million vs. $16.11 million estimated - BLINCYTO: $23.91 million vs. $20.42 million estimated - KYPROLIS: $19.73 million vs. $16.51 million estimated - Collaboration revenue was $8.75 million, exceeding the $6.49 million estimate [4] Market Performance - BeiGene's shares have returned +15.4% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Q1 2025 Results This presentation is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. All trademarks in this presentation are the property of their respective owners. This presentation includes U.S. generally accepted accounting principles ("GAAP") and non-GAAP financial measures. Reconciliations between these two measures are provided in the appendix to this presentation. Some of the clinical data ...

本文源自：金融界 作者：行情君 百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新 型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。 最新一期业绩显示，2024年年报，公司实现营业收入272.14亿元，同比56.19%；净利润-4978287000.0 元，同比25.87%，销售毛利率84.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8百济神州-67.20-67.2013.843345.35亿行业平均 57.2745.109.66181.27亿行业中值38.9936.382.8172.21亿1优宁维-1970.71245.081.2124.87亿2万泰生 物-1148.16780.856.79829.54亿3仁度生物-149.24-196.671.6815.36亿4诺思兰德-116.73-105.0214.6747.45亿 5通化东宝-97.37-337.862.22144.34亿6诺诚健华-81.88-81.885.36360.80亿7双鹭药业-68.61-90.991.2067.39 亿9康希诺- ...

4月30日，百济神州今日收盘261.18元，上涨5.78%，最新市净率15.14，总市值3659.76亿元。 截至2024年年报，共有219家机构持仓百济神州，其中基金218家、券商1家，合计持股数3794.77万股， 持股市值90.63亿元。 百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新 型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。 最新一期业绩显示，2024年年报，公司实现营业收入272.14亿元，同比56.19%；净利润-4978287000.0 元，同比25.87%，销售毛利率84.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)7百济神州-73.51-73.5115.143659.76亿行业平均 56.4644.8710.16184.98亿行业中值37.4836.522.7573.51亿1优宁维-1916.46238.331.1824.19亿2万泰生 物-1145.36778.956.78827.52亿3仁度生物-143.76-189.451.6214.80亿4诺思兰德-121.12- ...